Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

H Zhang, X Yue, Z Chen, C Liu, W Wu, N Zhang, Z Liu… - Molecular Cancer, 2023 - Springer
Despite centuries since the discovery and study of cancer, cancer is still a lethal and
intractable health issue worldwide. Cancer-associated fibroblasts (CAFs) have gained much …

[HTML][HTML] Germline TP53 pathogenic variants and breast cancer: A narrative review

E Blondeaux, L Arecco, K Punie, R Graffeo… - Cancer treatment …, 2023 - Elsevier
Approximately 10% of breast cancers are associated with the inheritance of a pathogenic
variant (PV) in one of the breast cancer susceptibility genes. Multiple breast cancer …

Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

S Loibl, F André, T Bachelot, CH Barrios… - Annals of …, 2024 - annalsofoncology.org
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
- Annals of Oncology Skip to Main Content Advertisement Annals of Oncology European …

Pregnancy after breast cancer in young BRCA carriers: an international hospital-based cohort study

M Lambertini, E Blondeaux, E Agostinetto, AS Hamy… - JAMA, 2024 - jamanetwork.com
Importance Young women with breast cancer who have germline pathogenic variants
inBRCA1orBRCA2face unique challenges regarding fertility. Previous studies …

Abemaciclib, palbociclib, and ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer

M Cejuela, A Gil-Torralvo, MÁ Castilla… - International Journal of …, 2023 - mdpi.com
By the end of 2020, there were more than 8 million women alive who had received a breast
cancer diagnosis in the previous 5 years, making it the most prevalent neoplasia in the …

Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor–positive breast cancer after chemotherapy: an 8-year follow-up of the …

SY Baek, WC Noh, SH Ahn, HA Kim, JM Ryu… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To determine the updated long-term outcomes of the Addition of Ovarian
Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who …

A tumoricidal lipoprotein complex electrostatically stabilized on mesoporous silica as nanotherapeutics and nanoadjuvant for potentiating immunotherapy of triple …

W Pei, Y Li, Y Wu, Y Wu, L Cai, S Wang… - Advanced Functional …, 2023 - Wiley Online Library
As the most aggressive subtype, triple‐negative breast cancer (TNBC) without definitive
targets represents a high probability of metastasis. Nevertheless, the presence of high‐level …

Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes

L Ma, B Yang, J Wu - Cancer Treatment Reviews, 2024 - Elsevier
Breast cancer diagnosed in premenopausal women tends to be more aggressive and the
benefit of ovarian function suppression (OFS), at least in certain groups of patients, is well …

[HTML][HTML] 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

F Cardoso, S Paluch-Shimon, E Schumacher-Wulf… - The breast, 2024 - Elsevier
This manuscript describes the Advanced Breast Cancer (ABC) international consensus
guidelines updated at the last two ABC international consensus conferences (ABC 6 in …

Accuracy of breast ultrasonography and mammography in comparison with postoperative histopathology in breast cancer patients after neoadjuvant chemotherapy

G Schmidt, S Findeklee, G del Sol Martinez… - Diagnostics, 2023 - mdpi.com
Introduction: Nowadays chemotherapy in breast cancer patients is optionally applied
neoadjuvant, which allows for testing of tumor response to the chemotherapeutical treatment …